Among 5,014 prostate cancer cases, class 1B FOXA1 alterations were the most prevalent, whereas the pathognomonic class 2 (R219) alterations were the rarest (but enriched in NEPC samples). This evidence concerns the gene FOXA1 and Familial prostate cancer.